Neuroendocrine Tumor Treatment Market, By Therapy Type (Somatostatin Analog Therapy, Peptide Receptor Radionuclide Therapy (PRRT), Targeted Therapy and Chemotherapy), By Drug Class, By Tumor Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
|
Report ID
AV2933
|
Published Date
December 2024
|
Pages
387
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Neuroendocrine Tumor Treatment Market size was valued at USD 2,510.21 Million in 2023, expanding at a CAGR of 9.10% from 2024 to 2032.
The Neuroendocrine Tumor Treatment Market focuses on therapies designed to manage neuroendocrine tumors (NETs), which originate from neuroendocrine cells and can occur in various organs. With an increasing global incidence of NETs—affecting approximately 6.98 cases per 100,000 people—the demand for effective treatment options is on the rise. Rising awareness about NETs, advancements in targeted therapies, and the growing number of clinical trials contribute significantly to market growth. However, high treatment costs and a lack of knowledge among healthcare professionals can hinder market expansion. Opportunities lie in the development of novel therapeutics and combination therapies, along with the potential for personalized medicine, which could enhance treatment efficacy. As healthcare systems evolve, the integration of advanced diagnostic techniques, such as PET scans and molecular imaging, is anticipated to improve patient outcomes and drive further growth in the market.
Neuroendocrine Tumor Treatment Market- Market Dynamics
Growing Number of Clinical Trials Accelerates Innovation in the Neuroendocrine Tumor Treatment Market
The growing number of clinical trials is significantly accelerating innovation in the neuroendocrine tumor (NET) treatment market, reflecting an increasing focus on developing targeted therapies. For instance, in 2021, the National Institutes of Health (NIH) reported over 350 active clinical trials specifically for NETs, highlighting the urgency to explore new treatment avenues. Pharmaceutical companies such as Novartis and Ipsen have invested heavily in clinical research to evaluate novel agents, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Furthermore, initiatives like the European Neuroendocrine Tumor Society (ENETS) have been instrumental in promoting collaborative research efforts, enabling faster advancements in treatment protocols. As a result, these efforts are anticipated to yield promising new therapies that enhance patient outcomes and quality of life for those diagnosed with neuroendocrine tumors.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Novartis AG
Pfizer Inc.
Ipsen S.A.
Advanced Accelerator Applications S.A.
Merck & Co., Inc.
AstraZeneca PLC
Roche Holding AG
Bristol-Myers Squibb Company
Bayer AG
GlaxoSmithKline plc
Eli Lilly and Company
Sanofi S.A.
Boehringer Ingelheim GmbH
Teva Pharmaceutical Industries Ltd.
Hutchison China MediTech Limited (Hutchmed)
Lexicon Pharmaceuticals, Inc.
Others
GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032
Somatostatin Analog Therapy
Peptide Receptor Radionuclide Therapy (PRRT)
Targeted Therapy
Chemotherapy
GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
Somatostatin Analogs
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Alkylating Agents
GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY TUMOR TYPE- MARKET ANALYSIS, 2019 - 2032
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Lung Neuroendocrine Tumors
Others
GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
Hospitals
Cancer Specialty Clinics
Research Institutes
GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
o The U.S.
o Canada
Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Russia
o Netherlands
o Sweden
o Poland
o Rest of Europe
Asia Pacific
o India
o China
o South Korea
o Japan
o Australia
o Thailand
o Indonesia
o Philippines
o Rest of APAC
Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
The Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Neuroendocrine Tumor Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Neuroendocrine Tumor Treatment Market Snippet by Therapy Type
2.1.2. Neuroendocrine Tumor Treatment Market Snippet by Drug Class
2.1.3. Neuroendocrine Tumor Treatment Market Snippet by Tumor Type
2.1.4. Neuroendocrine Tumor Treatment Market Snippet by End-User
2.1.5. Neuroendocrine Tumor Treatment Market Snippet by Country
2.1.6. Neuroendocrine Tumor Treatment Market Snippet by Region
2.2. Competitive Insights
3. Neuroendocrine Tumor Treatment Key Market Trends
3.1. Neuroendocrine Tumor Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Neuroendocrine Tumor Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Neuroendocrine Tumor Treatment Market Opportunities
3.4. Neuroendocrine Tumor Treatment Market Future Trends
4. Neuroendocrine Tumor Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Neuroendocrine Tumor Treatment Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Neuroendocrine Tumor Treatment Market Landscape
6.1. Neuroendocrine Tumor Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Neuroendocrine Tumor Treatment Market – By Therapy Type
7.1. Overview
7.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
7.1.2. Somatostatin Analog Therapy
7.1.3. Peptide Receptor Radionuclide Therapy (PRRT)
7.1.4. Targeted Therapy
7.1.5. Chemotherapy
8. Neuroendocrine Tumor Treatment Market – By Drug Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
8.1.2. Somatostatin Analogs
8.1.3. Tyrosine Kinase Inhibitors
8.1.4. mTOR Inhibitors
8.1.5. Alkylating Agents
9. Neuroendocrine Tumor Treatment Market – By Tumor Type
9.1. Overview
9.1.1. Segment Share Analysis, By Tumor Type, 2023 & 2032 (%)
9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
9.1.3. Lung Neuroendocrine Tumors
9.1.4. Others
10. Neuroendocrine Tumor Treatment Market – By End-User
10.1. Overview
10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
10.1.2. Hospitals
10.1.3. Cancer Specialty Clinics
10.1.4. Research Institutes
11. Neuroendocrine Tumor Treatment Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Neuroendocrine Tumor Treatment Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Neuroendocrine Tumor Treatment Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.9. Italy
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.9.5. Italy Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.10. United Kingdom
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.10.5. United Kingdom Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.11. France
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.11.5. France Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.12. Russia
11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.2. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.12.4. Russia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.13. Netherlands
11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.2. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.13.4. Netherlands Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.2. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.15. Poland
11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.2. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.15.4. Poland Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.16. Rest of Europe
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.16.5. Rest of the Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Neuroendocrine Tumor Treatment Key Manufacturers in Asia Pacific
11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.6. Asia Pacific Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.8. India
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.8.5. India Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.9. China
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.9.5. China Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.13. Thailand
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.13.5. Thailand Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.14. Indonesia
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.14.5. Indonesia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
11.5.1. Overview
11.5.2. Neuroendocrine Tumor Treatment Key Manufacturers in Latin America
11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.6. Latin America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
11.6.1. Overview
11.6.2. Neuroendocrine Tumor Treatment Key Manufacturers in Middle East and Africa
11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.6. Middle East and Africa Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Neuroendocrine Tumor Treatment Industry
12.1. Competitive Dashboard
12.2. Company Profiles
12.2.1. Novartis AG
12.2.2. Pfizer Inc.
12.2.3. Ipsen S.A.
12.2.4. Advanced Accelerator Applications S.A.
12.2.5. Merck & Co., Inc.
12.2.6. AstraZeneca PLC
12.2.7. Roche Holding AG
12.2.8. Bristol-Myers Squibb Company
12.2.9. Bayer AG
12.2.10. GlaxoSmithKline plc
12.2.11. Eli Lilly and Company
12.2.12. Sanofi S.A.
12.2.13. Boehringer Ingelheim GmbH
12.2.14. Teva Pharmaceutical Industries Ltd.
12.2.15. Hutchison China MediTech Limited (Hutchmed)
12.2.16. Lexicon Pharmaceuticals, Inc.
12.2.17. Others
13. 360 Degree Analyst View
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
